Drug DevelopmentThe New Drug Application (NDA) for Bysanti™ (milsaperidone) has been accepted for review by the FDA with no potential review issues identified.
Financial PerformanceVanda reported its 1Q25 financial results with a top-line revenue totaling $50M, beating the forecast of $45M.
Sales GrowthVanda's neuropsychiatry portfolio, including iloperidone and milsaperidone, is expected to drive significant future sales growth, potentially exceeding $1 billion by 2030.